MiMedx Group Inc (MDXG) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
MiMedx Group Inc stock (MDXG) is currently trading at $4.10. MiMedx Group Inc PE ratio is 12.88. MiMedx Group Inc PS ratio (Price-to-Sales) is 1.46. Analyst consensus price target for MDXG is $9.67. WallStSmart rates MDXG as Moderate Buy.
- MDXG PE ratio analysis and historical PE chart
- MDXG PS ratio (Price-to-Sales) history and trend
- MDXG intrinsic value — DCF, Graham Number, EPV models
- MDXG stock price prediction 2025 2026 2027 2028 2029 2030
- MDXG fair value vs current price
- MDXG insider transactions and insider buying
- Is MDXG undervalued or overvalued?
- MiMedx Group Inc financial analysis — revenue, earnings, cash flow
- MDXG Piotroski F-Score and Altman Z-Score
- MDXG analyst price target and Smart Rating
MiMedx Group Inc
📊 No data available
Try selecting a different time range
MDXG Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · MiMedx Group Inc (MDXG)
MDXG trades at a significant discount to its Graham intrinsic value of $14.98, offering a 65% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
MiMedx Group Inc (MDXG) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/sales, revenue growth. Overall metrics suggest strong investment potential with favorable risk/reward.
MiMedx Group Inc (MDXG) Key Strengths (5)
Earnings per share surging 99.50% year-over-year
73.20% of shares held by major funds and institutions
Every $100 of equity generates $22 in profit
Paying $1.46 for every $1 of annual revenue
Strong revenue growth at 27.10% annually
Supporting Valuation Data
MiMedx Group Inc (MDXG) Areas to Watch (5)
Paying a premium for growth, expensive relative to earnings expansion
Small-cap company with higher risk but more growth potential
Decent operational efficiency, solid but not exceptional
Fairly priced relative to book value
Decent profitability, keeps $12 per $100 revenue
MiMedx Group Inc (MDXG) Detailed Analysis Report
Overall Assessment
This company scores 72/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 5.4/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Return on Equity. Valuation metrics including Price/Sales (1.46) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 21.60%. Growth metrics are encouraging with Revenue Growth at 27.10%, EPS Growth at 99.50%.
The Bear Case
The primary concerns are PEG Ratio, Market Cap, Operating Margin. Some valuation metrics including PEG Ratio (2.97), Price/Book (2.39) suggest expensive pricing. Profitability pressure is visible in Operating Margin at 17.80%, Profit Margin at 11.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 21.60% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 27.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of EPS Growth and Institutional Own. makes a compelling case at current levels. The key risk is PEG Ratio, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MDXG Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MDXG's Price-to-Sales ratio of 1.46x trades at a deep discount to its historical average of 23.73x (3th percentile). The current valuation is 99% below its historical high of 253.45x set in Dec 2010, and 112% above its historical low of 0.69x in Dec 2018. Over the past 12 months, the PS ratio has compressed from ~3.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for MiMedx Group Inc (MDXG) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
MiMedx Group Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 419M with 27% growth year-over-year. Profit margins of 11.6% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 27% YoY, reaching 419M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 21.6% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Margin expansion: can MiMedx Group Inc push profit margins above 15% as the business scales?
Growth sustainability: can MiMedx Group Inc maintain 27%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.60, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact MiMedx Group Inc.
Bottom Line
MiMedx Group Inc offers an attractive blend of growth (27% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About MiMedx Group Inc(MDXG)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.